Earn points on every order New products in stock Free 51-page beginner’s guide
← Back to Compound Library

GHRP-6

The original ghrelin-mimetic GH-releaser. Same GH-boosting mechanism as GHRP-2 but with a much stronger appetite kick, favored when the goal is eating more and gaining.

Research referenceCommunity compiled

Molecular profile

The molecule itself: sequence, composition, mass, target, and registry identifiers.

Molecular formula
C₄₆H₅₆N₁₂O₆
Average mass
873.0 Da
Registry
PubChem CID 4345065
Receptor / pathway
GHSR1a
Formula, mass and identifiers from PubChem CID 4345065.
Research & reference information

This profile compiles research and community-sourced reference information for educational purposes. Information may evolve as research and community knowledge develop. It is not individualized medical advice.

Overview

GHRP-6 is a first-generation synthetic hexapeptide growth hormone secretagogue renowned for triggering dramatic growth hormone release alongside intense appetite stimulation.

What problem it targets: It targets low growth hormone levels, slow athletic recovery, muscle wasting, and severe appetite loss in individuals struggling to consume enough calories to gain mass.

What It Does

• Potently activates ghrelin receptors: Strongly binds pituitary and hypothalamic GHS-R1a receptors, eliciting a massive, immediate pulse of endogenous growth hormone.

• Induces acute, intense hunger (hyperphagia): Mimics the hunger hormone ghrelin in the hypothalamus, triggering ravenous food cravings within 20 to 30 minutes of administration.

• Enhances gut motility and protective tissue repair: Stimulates stomach emptying and mucosal blood flow, aiding digestion and nutrient assimilation during heavy training cycles.

• Realistic expectations: Delivers immediate, pronounced hunger alongside rapid GH release. Produces mild water retention and increases in prolactin and cortisol at higher doses.

Reconstitution

Vial sizeBAC water / SolventConcentration
5 mg+ 1 mL5 mg/mL
10 mg+ 2 mL5 mg/mL

Protocol

PhaseFrequencyDoseUnits (2 mg/mL)Notes
Weeks 1–22×/day100 mcg5uExpect strong hunger ~20–30 min after dosing. AM fasted + pre-bed.
Weeks 3–122–3×/day200 mcg10uWorking dose. ~1 mcg/kg saturates the GH response; more mainly adds cortisol/prolactin.
Off4 weeks––Prevents ghrelin-receptor downregulation. Cycle: 8–12 weeks on / 4 weeks off. Timing: Empty stomach, no food 30 min after. The hunger surge is the tell that it’s working (and why it suits bulking). Saturation: plateaus ~1 mcg/kg. Women: Women need more GH but get a bigger bump from ghrelin-types, though these raise prolactin, which can disrupt cycles/ovulation (watch for missed periods). Oral estrogen blunts IGF-1. Men: Men overshoot the IGF-1 ceiling more easily (aim mid-normal); high prolactin lowers libido and testosterone, switch to a cleaner option if it climbs.

Handling & Stacking

Injection site
SubQ, abdomen. Rotate.
Storage
Freeze-dried: -4°F. Reconstituted: 36–46°F. Best used within 28 days, otherwise potency gradually fades over ~3–4 weeks (structure-based estimate, no published data).
Side effects
Pronounced hunger, flushing/warmth, water retention, mild cortisol/prolactin bump. Hunger fades with continued use.
What to expect
  • Strong appetite and improved sleep early; recovery and body-composition gains over 8–12 weeks.
  • Best in a GHRH + GHRP stack during a gaining phase.
  • Supply math 5mg → 7 vials | 10mg → 4 vials (12-wk @ 200 mcg × 2/day)
Pairs well with
CJC-1295 (No DAC) / Sermorelin (GHRH + GHRP synergy); Ipamorelin (if appetite is unwanted); Wolverine Blend (recovery)
Avoid
Active malignancy. Severe insulin resistance. Cutting phases (appetite). Elevated baseline prolactin
Approved drug
Somatropin (HGH) is approved for growth-hormone deficiency and tesamorelin (Egrifta) for HIV lipodystrophy. Secretagogues like this one are off-label.

Safety & Patient Education

Contraindications
Active malignancy of any kind (GH/IGF-1 can promote tumor growth) Severe diabetic retinopathy Acute critical illness (per somatropin label) Pregnancy and lactation
Warnings
Strong appetite stimulation, can drive unwanted weight gain, poor glycemic control and insulin resistance with sustained use Cortisol and prolactin elevation (similar to GHRP-2) Fluid retention, carpal tunnel, joint pain with extended use IGF-1 elevation: theoretical malignancy promotion beyond physiological ranges Requires off cycles to prevent receptor desensitization
Drug interactions
Glucocorticoids: blunt GH response Insulin / antidiabetics: GH + appetite worsen glycemic control, monitor closely Levothyroxine: GH lowers free T4, recheck TSH/fT4 quarterly Oral estrogens: blunt GH-stimulated IGF-1
Labs
  • IGF-1 (baseline + Week 8 + end) Fasting glucose / HbA1c (baseline + end), especially given appetite effect Prolactin if symptomatic Age-appropriate cancer screening before starting Out of range?
  • IGF-1 above your age range = too much growth signal (feeds hidden cancer, enlarges organs) → drop the dose; rising glucose/HbA1c = sugar creeping up.
Stop criteria
Fasting glucose rises >20 mg/dL above baseline IGF-1 above upper limit of normal for age Uncontrolled appetite-driven weight gain New persistent joint pain, carpal tunnel, or vision changes
Patient education
Expect strong hunger, plan meals or it can sabotage a cut Keep doses near the saturating range; more isn’t better Fasted dosing; protect sleep Not for use during active malignancy or pregnancy; report new lumps or vision changes
References
researchdosing · peptidedosages · PubMed · thepeptidereport · Span 2000 · Weissberger 1991